PE20060332A1 - Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados - Google Patents

Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados

Info

Publication number
PE20060332A1
PE20060332A1 PE2005000284A PE2005000284A PE20060332A1 PE 20060332 A1 PE20060332 A1 PE 20060332A1 PE 2005000284 A PE2005000284 A PE 2005000284A PE 2005000284 A PE2005000284 A PE 2005000284A PE 20060332 A1 PE20060332 A1 PE 20060332A1
Authority
PE
Peru
Prior art keywords
alkyl
diabetes
naphthyridine
naphthyridin
phenyl
Prior art date
Application number
PE2005000284A
Other languages
English (en)
Spanish (es)
Inventor
Rainer Heurich
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20060332A1 publication Critical patent/PE20060332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2005000284A 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados PE20060332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55297104P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
PE20060332A1 true PE20060332A1 (es) 2006-06-01

Family

ID=35056657

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000284A PE20060332A1 (es) 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados

Country Status (6)

Country Link
AR (1) AR048088A1 (zh)
GT (1) GT200500049A (zh)
PE (1) PE20060332A1 (zh)
TW (1) TW200538124A (zh)
UY (1) UY28805A1 (zh)
WO (1) WO2005091857A2 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2839395A1 (en) 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
JOP20180097B1 (ar) * 2018-10-22 2023-03-28 Univ Of Jordan مشتقات 1.8 - نفثاريدين الغلايكوزيلية و طرق تحضيرها و استخدامها في معالجة الالتهابات الميكروبية

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL51092A0 (en) * 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Also Published As

Publication number Publication date
WO2005091857A2 (en) 2005-10-06
GT200500049A (es) 2005-10-24
AR048088A1 (es) 2006-03-29
WO2005091857A3 (en) 2006-10-05
TW200538124A (en) 2005-12-01
UY28805A1 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
PE20060332A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados
PE20110383A1 (es) Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
PE20070498A1 (es) Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CO5700726A2 (es) Compuestos organicos
ES2530431T3 (es) Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
CO6180449A2 (es) Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis
PE20090217A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
PE20060833A1 (es) Derivados de purina como agonistas del receptor a2a de adenosina
PE20071328A1 (es) Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso
CO6160266A2 (es) Derivado de oxopirazina y herbicida
PE20090330A1 (es) Compuestos heterociclicos inhibidores de transcriptasa inversa y composicion farmaceutica que comprende a dicho compuesto
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
PE20060836A1 (es) Procedimientos para preparar eteres aromaticos
PE20090484A1 (es) Moduladores de calicreina 7
ATE532834T1 (de) Pigmentdispersion und tintenzusammensetzung, die diese verwendet
PL1961734T3 (pl) Związek aminowy i jego zastosowanie do celów medycznych
ECSP088926A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina
PE20000134A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina
CO5590963A2 (es) Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4
PE20230769A1 (es) Antagonistas del receptor de adenosina a2a

Legal Events

Date Code Title Description
FC Refusal